Assay News and Research

RSS

BioTek’s MultiFlo™ FX now available with Random Access Dispense technology

BioTek’s MultiFlo™ FX is now available with optional RAD™ (Random Access Dispense) technology to further extend its application range and flexibility. RAD technology offers single-channel dispensing to random individual microplate wells along with rapid reagent dispensing into large volume wells of 6- to 24- well microplates. MultiFlo FX can also be separately configured with an optional wash module for 6- to 384-well plates.

4 Apr 2014

QIAGEN launches new products for next-generation sequencing applications

QIAGEN N.V. today announced two important new product launches which address workflow challenges in next-generation sequencing (NGS) applications.

From QIAGEN Manchester Limited 3 Apr 2014

AB Sciex launches immunosuppressants kit to improve health care

Every organ transplant patient in the world faces the potential danger of his/her body rejecting a new organ, such as a heart, kidney or liver. Immunosuppressant drugs are required to help prevent rejection.

2 Apr 2014

Venaxis files 510(k) premarket submission with FDA for APPY1 Test

Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration.

31 Mar 2014

Study: Guinea pigs and mice can be replaced with non-animal skin sensitization method

Guinea pigs and mice can be replaced with a non-animal skin sensitization method that uses a human-derived skin model, according to a study presented today by the PETA International Science Consortium, Ltd., at the Society of Toxicology's annual meeting.

27 Mar 2014

SLU researchers awarded NIH grants to search for a drug to cure hepatitis B

Two grants from the National Institutes of Health will allow Saint Louis University researchers to build on breakthroughs in understanding the hepatitis B virus and begin the search for a drug to cure - not just halt - the illness.

26 Mar 2014

Stem cell research opens doors to potential new treatments for bipolar disorder

What makes a person bipolar, prone to manic highs and deep, depressed lows? Why does bipolar disorder run so strongly in families, even though no single gene is to blame? And why is it so hard to find new treatments for a condition that affects 200 million people worldwide?

26 Mar 2014

New technology gives tool to examine membrane proteins in natural environment of human cell

Scientists have a better way to study human proteins - large molecules that are part of every cell in the body - thanks to a new technology developed by University of Toronto researchers.

25 Mar 2014

Cell-free DNA analysis allows noninvasive tumour genotype monitoring

Noninvasive tumour genotyping using cell-free plasma DNA analysis is feasible, say US researchers who believe the technique will aid patient diagnosis and monitoring.

24 Mar 2014

ChromaTrap™ Chromatin Immunoprecipitation technology receives positive commentary in published paper

Porvair Sciences reports on positive commentary by researchers in published papers citing how using the fast, sensitive ChromaTrap™ Chromatin Immunoprecipitation (ChIP) technology has benefited their research.

From Chromatrap® - Porvair Sciences Ltd 18 Mar 2014

Trovagene reports net loss of $1 million for fourth quarter 2013

Trovagene, Inc., a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.

18 Mar 2014

UC Davis MIND Institute named Intellectual and Developmental Disabilities Research Center

The UC Davis MIND Institute has been named an Intellectual and Developmental Disabilities Research Center, through a prestigious grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health - a distinction held by only a handful of neurodevelopmental centers nationwide committed to the diagnosis, prevention, treatment and amelioration of developmental disorders such as autism, fragile X syndrome and Down syndrome.

14 Mar 2014

Venaxis' APPY1 Test for appendicitis shows positive results in pivotal U.S. study

Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study.

14 Mar 2014

Blocking function of enzyme slows spread of pancreatic cancer, say researchers

A research team from Imperial College London has shown that blocking the function of an enzyme known as Hhat slows the growth and spread of pancreatic cancer, by preventing a protein called Hedgehog from stimulating nearby normal cells to help the cancer.

13 Mar 2014

Innovative study uses pharmacogenomic test to treat patients with psychotic disorders

ValueOptions, Inc. a health improvement company specializing in mental and emotional well-being and recovery, and Genomind, a personalized medicine company, today announced an innovative study that uses pharmacogenomic testing to treat patients diagnosed with psychotic disorders, including schizophrenia and bipolar disorder.

11 Mar 2014

Promethera Biosciences, EMD Millipore partner to develop ready-to-use microfluidic perfusion liver assay

Promethera Biosciences, a company that develops innovative therapies for the treatment of liver diseases, today announces a collaboration with EMD Millipore to develop an improved ready-to-use microfluidic perfusion liver assay. This new product is designed to perform more robust studies in pre-clinical toxicity and drug metabolism.

11 Mar 2014

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Illumina, Inc. and WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.

From Illumina, Inc. 10 Mar 2014

Agendia co-founder to be honored with 2014 European Union Prize for Women Innovators

Agendia co-founder Laura van 't Veer, Ph.D., will receive a 2014 European Union Prize for Women Innovators in ceremonies next Monday. Dr. van 't Veer, of the Netherlands, is the inventor of Agendia's MammaPrint® breast cancer test.

7 Mar 2014

Boston Heart Diagnostics announces commercial launch of FDA-cleared MPO test

Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.

6 Mar 2014

ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO.